News | May 19, 2023
Thermo Fisher Scientific expands ImmunoCAP test availability across U.S.
Testing supporting allergy diagnosis now accessible to more people in more communities
Testing supporting allergy diagnosis now accessible to more people in more communities
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
Celgene agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S.
The ninth acquisition since 2018
The product will be manufactured at Lupin's facility in Goa, India.
Subscribe To Our Newsletter & Stay Updated
